Renalytix Reports Full Year Fiscal 2023 Results
September 28, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
September 25, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday,...
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
September 07, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled...
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
August 03, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical...
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
July 21, 2023 07:00 ET
|
Renalytix plc
Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney...
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
July 07, 2023 07:00 ET
|
Renalytix plc
12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in...
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
July 03, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled...
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
June 29, 2023 18:01 ET
|
Renalytix plc
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United...
KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences
June 15, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
June 09, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...